| Candice Geary, MD | |
|
612 Kingsborough Sq, Suite 200, Chesapeake, VA 23320-5041 | |
| (757) 436-0167 | |
| (757) 436-0236 |
| Full Name | Candice Geary |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 30 Years |
| Location | 612 Kingsborough Sq, Chesapeake, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639286784 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101057750 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chesapeake Regional Medical Center | Chesapeake, VA | Hospital |
| The Outer Banks Hospital, Inc | Nags head, NC | Hospital |
| Sentara Virginia Beach General Hospital | Virginia beach, VA | Hospital |
| Sentara Leigh Hospital | Norfolk, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Womens Care Plc | 8820998156 | 140 |
| Mid-atlantic Womens Care Plc | 8820998156 | 140 |
News Archive
BioSante Pharmaceuticals, Inc. today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events.
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
Researchers in the U.S. say that more and more Americans are missing out when it comes to receiving full medical care because they are too obese to fit into scanners or their fat is too dense for X-rays or sound waves to penetrate.
A protein measured in a simple blood test may be a new biomarker to identify patients with the most serious form of asthma, Yale School of Medicine researchers report in the New England Journal of Medicine.
› Verified 8 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20040115000607 |
News Archive
BioSante Pharmaceuticals, Inc. today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events.
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
Researchers in the U.S. say that more and more Americans are missing out when it comes to receiving full medical care because they are too obese to fit into scanners or their fat is too dense for X-rays or sound waves to penetrate.
A protein measured in a simple blood test may be a new biomarker to identify patients with the most serious form of asthma, Yale School of Medicine researchers report in the New England Journal of Medicine.
› Verified 8 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Mammography Center |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20080611000246 |
News Archive
BioSante Pharmaceuticals, Inc. today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events.
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
Researchers in the U.S. say that more and more Americans are missing out when it comes to receiving full medical care because they are too obese to fit into scanners or their fat is too dense for X-rays or sound waves to penetrate.
A protein measured in a simple blood test may be a new biomarker to identify patients with the most serious form of asthma, Yale School of Medicine researchers report in the New England Journal of Medicine.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candice Geary, MD 612 Kingsborough Sq, Ste 200, Chesapeake, VA 23320-5054 Ph: (757) 547-2322 | Candice Geary, MD 612 Kingsborough Sq, Suite 200, Chesapeake, VA 23320-5041 Ph: (757) 436-0167 |
News Archive
BioSante Pharmaceuticals, Inc. today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events.
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
Researchers in the U.S. say that more and more Americans are missing out when it comes to receiving full medical care because they are too obese to fit into scanners or their fat is too dense for X-rays or sound waves to penetrate.
A protein measured in a simple blood test may be a new biomarker to identify patients with the most serious form of asthma, Yale School of Medicine researchers report in the New England Journal of Medicine.
› Verified 8 days ago
Mrs. Rachel D Lee, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3802 Poplar Hill Rd, Suite C, Chesapeake, VA 23321 Phone: 757-673-8383 Fax: 757-483-9350 | |
Pamela B Smith, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3806 Poplar Hill Rd Ste C, Chesapeake, VA 23321 Phone: 757-483-4600 Fax: 757-484-2323 | |
Dr. Christian Manuel Perez, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 300 Medical Pkwy Ste 200, Chesapeake, VA 23320 Phone: 757-977-8500 Fax: 757-451-9694 | |
Craig H Ruetzel, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 824 Greenbrier Pkwy, Suite 100, Chesapeake, VA 23320 Phone: 757-410-7390 Fax: 757-410-7395 | |
Peter J Kemp, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 Medical Pkwy, Suite 300, Chesapeake, VA 23320 Phone: 757-548-3880 Fax: 757-548-3373 | |
Angela Ferebee, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 713 Volvo Pkwy, Ste 200, Chesapeake, VA 23320 Phone: 757-547-4500 Fax: 757-547-4502 | |
Michael P Grimes, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Medical Pkwy, Suite 202, Chesapeake, VA 23320 Phone: 757-436-2424 Fax: 757-436-7012 |